Assessment of inhibitor risk after switching from plasma-derived factor VIII concentrate to recombinant factor VIII (Brasil-RFVIII: brazilian study of inhibitor linked to recombinant factor VIII)

被引：0

作者：

Prezotti, A. ^{[1
,2
]}

Montalvao, S. ^{[1
]}

Marques, A. ^{[3
]}

Ferreira, C. ^{[4
]}

Oliveira, L. ^{[5
]}

Villaca, P. ^{[6
]}

Ferreira Filho, L. ^{[7
]}

Lorenzato, C. ^{[8
]}

Medina, S. ^{[1
]}

Araujo, F. ^{[9
]}

Ozelo, M. ^{[1
]}

机构：

[1] Univ Campinas UNICAMP, INCT SANGUE HEMOCTR UNICAMP, Campinas, SP, Brazil

[2] Hemoctr Espirito Santo, Hematol, Vitoria, Brazil

[3] HEMORIO, Hematol, Rio De Janeiro, Brazil

[4] Hemoctr Rio Grande do Sul HEMORS, Hematol, Porto Alegre, RS, Brazil

[5] Univ Sao Paulo USP Ribeirao Preto, Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil

[6] HCFMUSP Univ Sao Paulo, Hematol, Sao Paulo, Brazil

[7] HEMOCTR CEARA HEMOCE, Hematol, Fortaleza, Ceara, Brazil

[8] HEMOCTR PARANA HEMEPAR, Hematol, Curitiba, Parana, Brazil

[9] Hemoctr Pernambuco HEMOPE, Hematol, Recife, PE, Brazil

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PO286-MON

引用

页码：366 / 366

页数：1

共 50 条

[21] Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better [J].

Franchini, Massimo .

BLOOD TRANSFUSION, 2010, 8 (04) :292-296

[22] Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates [J].

Dingli, D ;

Gastineau, DA ;

Gilchrist, GS ;

Nichols, WL ;

Wilke, JL .

HAEMOPHILIA, 2002, 8 (05) :629-634

[23] FACTOR-VIII INHIBITOR ASSAYS USING PLASMA-DERIVED FVIII VERSUS RECOMBINANT FVIII - A COMPARATIVE-STUDY [J].

HILLMANWISEMAN, C ;

VITALE, C ;

LUSHER, J .

THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) :684-684

[24] Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro [J].

Astermark, J ;

Voorberg, J ;

Lenk, H ;

Dimichele, D ;

Shapiro, A ;

Tjönnfjord, G ;

Berntorp, E .

HAEMOPHILIA, 2003, 9 (05) :567-572

[25] Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better [J].

Mannucci, Pier Mannuccio .

BLOOD TRANSFUSION, 2010, 8 (04) :288-291

[26] Comparative stability of plasma derived and recombinant factor VIII [J].

Mankarious, S ;

Parti, R .

THROMBOSIS AND HAEMOSTASIS, 1997, :P2077-P2077

[27] Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study [J].

Miri, Syna ;

Rosendaal, Frits R. ;

Kavakli, Kaan ;

Eshghi, Peyman ;

Moghaddam, Soha Mohammadi ;

Scardo, Sara ;

Habibpanah, Behnaz ;

Elalfy, Mohsen ;

Halimeh, Susan ;

Nicolo, Gabriella ;

Gokcebay, Dilek ;

Ozbek, Namik ;

Celkan, Tiraje ;

Mohammadi, Ahmad ;

Karimi, Mehran ;

Shahsavani, Amin ;

Yilmaz, Baris ;

Albayrak, Canan ;

Gunes, Burcak ;

Kaya, Zuehre ;

Ay, Yilmaz ;

Akbayram, Sinan ;

Sarper, Nazan ;

Mannucci, Pier Mannuccio ;

Peyvandi, Flora .

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (08)

[28] RECENT ADVANCES IN THE PREPARATION OF PLASMA-DERIVED AND RECOMBINANT COAGULATION FACTOR-VIII [J].

BRAY, GL .

JOURNAL OF PEDIATRICS, 1990, 117 (03) :503-507

[29] Biochemical and immunochemical investigations of different plasma-derived and recombinant factor VIII products [J].

Josic, D ;

Stadler, M ;

Buchacher, A ;

Schulz, P ;

Schutz, R ;

Wiry, G ;

Schwinn, H .

THROMBOSIS AND HAEMOSTASIS, 1997, :P2095-P2095

[30] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIIA DO NOT CORRECT BLEEDING-TIME IN A RABBIT FACTOR-VIII INHIBITOR MODEL [J].

TURECEK, PL ;

SCHWARZ, HP .

THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) :986-986

← 1 2 3 4 5 →